introduced in Australia in 2013
does not have the anti-pseudomonal or VRE coverage of ceftobiprole
less effective against some Gram negatives
binds to the altered penicillin binding proteins produced by certain penicillin resistant bacteria
broad spectrum coverage includes E. coli, H. influenzae, Klebsiella pneumoniae, MRSA, penicillin non-susceptible Str. pneumoniae
used to Rx skin, soft tissue infections and community acquired pneumonia (with an adjunctive antibiotic such as clarithromycin, and clinical cure rates were a touch better than for ceftriaxone with clarithromycin)
90% renal excreted, half life 2.5hrs
10% develop a positive Coombs test
usual adult dose: 600mg iv infusion over 1hr bd